Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
J. Ley
No relevant relationships to disclose
B. A. Siegel
No relevant relationships to disclose
F. Dehdashti
No relevant relationships to disclose
J. Subramanian
No relevant relationships to disclose
G. Ansstas
No relevant relationships to disclose
T. Rachocki
No relevant relationships to disclose
J. Mathai
No relevant relationships to disclose
T. M. Wildes
No relevant relationships to disclose
D. I. Kuperman
No relevant relationships to disclose
D. Adkins
Honoraria - ImClone Systems; Lilly